安罗替尼联合依托泊苷口服治疗铂类耐药或难治性晚期卵巢癌的临床疗效观察  

Clinical Efficacy of Oral Administration of Anlotinib Combined with Etoposide in the Treatment of Patients with Platinum-Resistant or Refractory Advanced Ovarian Cancer

作　　者：姚书娜 姚志华 严正 王海英 褚俊峰 赵爽 刘艳艳 杨树军 YAO Shuna;YAO Zhihua;YAN Zheng;WANG Haiying;CHU Junfeng;ZHAO Shuang;LIU Yanyan;YANG Shujun(Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Zhengzhou 450000, China)

机构地区：[1]郑州大学附属肿瘤医院淋巴综合内科,河南郑州450000

出　　处：《中国医药导刊》2021年第2期100-103,共4页Chinese Journal of Medicinal Guide

基　　金：河南省科技攻关项目[项目编号:201702251,项目名称:MYD88(L265P)突变与弥漫大B细胞淋巴瘤预后相关性的研究]。

摘　　要：目的:通过观察门诊服用安罗替尼联合依托泊苷胶囊治疗的铂类耐药或难治性晚期卵巢癌患者,分析该联合治疗的疗效和安全性。方法:回顾性分析2018年6月至2020年4月在我科室经病理确诊且对铂类耐药或难治性晚期卵巢癌患者14例,均给予安罗替尼联合小剂量依托泊苷胶囊治疗。收集患者的治疗反应、毒副作用发生情况,计算有效率、疾病控制率、中位无进展生存时间。结果:截至末次随访时间2020年8月31日,部分缓解(PR)患者7例,疾病稳定(SD)患者5例,2例患者进展(PD),总有效率(ORR)为50.0%(7/14),疾病控制率(DCR)为85.7%(12/14)。中位无进展生存时间为6个月(95%CI:0.0,12.7)。14例患者中乏力、腹胀和食欲下降的发生率100%,均为1~2级。白细胞下降的发生率为64.7%,1例患者3级,1例患者4级,经减少依托泊苷服药时间(7 d)后降为1级;高血压的发生率为35.7%,均为1、2级。口腔黏膜炎发生率为21.4%,1例为3级黏膜炎。1例患者因4周期后出现2级窦性心动过缓停止该方案治疗。结论:安罗替尼联合依托泊苷胶囊口服治疗晚期卵巢癌毒副作用可耐受、疾病控制率高。Objective:To observe the efficacy and safety of the combination therapy of anlotinib and etoposide capsules in patients with platinum-resistant or refractory advanced ovarian cancer.Methods:From June 2018 to April 2020,14 patients with platinum resistant or refractory advanced ovarian cancer confirmed by pathology in our department were retrospectively analyzed.All patients were treated with arotinib combined with low-dose etoposide capsules.Therapeutic reaction and adverse reaction were collected.The effective rate,disease control rate and median progression free survival time were calculated.Results:The last follow-up time was August 31,2020.There were 7 cases of partial response(PR),5 cases of stable disease(SD),2 cases of progression of disease(PD),and the overall response rate(ORR)was 50.0%(7/14),disease control rate(DCR)was 85.7%(12/14).The median progression-free survival(PFS)was 6.0 months,95%CI=(0.0,12.7).The incidence of fatigue,abdominal distension and loss of appetite were all 100%in 14 patients,which were grade 1~2.The incidence of leukopenia was 64.7%,one patient was grade 3 and another was grade 4.After reducing the time of etoposide(7 days),it was reduced to grade 1.The incidence of hypertension was 35.7%,which was grade 1~2.The incidence of oral mucositis was 21.4%,and 1 case was grade 3.One patient stopped treatment because of grade 2 sinus bradycardia after 4 cycles.Conclusion:The combination of anlotinib with etoposide oral administration shows promising efficacy and manageable toxicities in patients with platinum-resistant or refractory advanced ovarian cancer.

关 键 词：安罗替尼 依托泊苷 卵巢癌 疗效 安全性 

分 类 号：R737.9[医药卫生—肿瘤]